GB201819721D0 - Target for anti-cancer therapy - Google Patents

Target for anti-cancer therapy

Info

Publication number
GB201819721D0
GB201819721D0 GBGB1819721.0A GB201819721A GB201819721D0 GB 201819721 D0 GB201819721 D0 GB 201819721D0 GB 201819721 A GB201819721 A GB 201819721A GB 201819721 D0 GB201819721 D0 GB 201819721D0
Authority
GB
United Kingdom
Prior art keywords
target
cancer therapy
cancer
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1819721.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHOREMOST Ltd
Original Assignee
PHOREMOST Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHOREMOST Ltd filed Critical PHOREMOST Ltd
Priority to GBGB1819721.0A priority Critical patent/GB201819721D0/en
Publication of GB201819721D0 publication Critical patent/GB201819721D0/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
GBGB1819721.0A 2018-12-03 2018-12-03 Target for anti-cancer therapy Ceased GB201819721D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB1819721.0A GB201819721D0 (en) 2018-12-03 2018-12-03 Target for anti-cancer therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1819721.0A GB201819721D0 (en) 2018-12-03 2018-12-03 Target for anti-cancer therapy

Publications (1)

Publication Number Publication Date
GB201819721D0 true GB201819721D0 (en) 2019-01-16

Family

ID=65024925

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1819721.0A Ceased GB201819721D0 (en) 2018-12-03 2018-12-03 Target for anti-cancer therapy

Country Status (1)

Country Link
GB (1) GB201819721D0 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017182783A2 (en) 2016-04-18 2017-10-26 Phoremost Limited Inactivation of dna repair as an anticancer therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017182783A2 (en) 2016-04-18 2017-10-26 Phoremost Limited Inactivation of dna repair as an anticancer therapy

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHEUN-ONG ET AL., CHEMISTRY AND BIOLOGY, vol. 20, no. 5, 23 May 2013 (2013-05-23), pages 648 - 659
FABRIZIO ET AL., JOURNAL OF GASTROINTESTINAL ONCOLOGY
GENOME RES., vol. 24, 2014, pages 1740 - 1750
GERMANO ET AL., NATURE, vol. 552, no. 7683, 2017, pages 116 - 120
HUMAN MOLECULAR GENETICS, vol. 22, no. 14, 15 July 2013 (2013-07-15), pages 2820 - 2828
NASIRI ET AL., BIOORG. MED. CHEM. LETT., vol. 26, 2016, pages 4433 - 4435
O'CONNOR, MOLECULAR CELL REVIEW, vol. 60, no. 4, 19 November 2015 (2015-11-19), pages 547 - 60
PARSONS ET AL., CELL, vol. 75, no. 6, 17 December 1993 (1993-12-17), pages 1227 - 36
TURAJLIC ET AL., LANCET ONCOL., vol. 18, 2017, pages 1009 - 21

Similar Documents

Publication Publication Date Title
IL254705B (en) Combination therapy for cancer
IL270905A (en) Anti-cancer combination therapy
GB201804255D0 (en) Macrophage-based therapy
ZA202005847B (en) Cancer therapy
IL282330A (en) Therapeutic compounds
GB201819853D0 (en) Therapy
IL282093A (en) Combination therapy for cancer
GB201707212D0 (en) Gene therapy for ciliopathies
GB201808150D0 (en) Therapeutic compounds
HK1254687A1 (en) Combination therapy for cancer
SG11202103691SA (en) Target for anti-cancer therapy
GB201819721D0 (en) Target for anti-cancer therapy
GB201904765D0 (en) Target for anti-cancer therapy
GB201717034D0 (en) Targets for anti-cancer therapy
GB201805557D0 (en) Therapy for ophthalmogical condtions
HRP20210383T8 (en) Combination therapy for cancer
GB201815012D0 (en) Target
GB201820895D0 (en) Therapy
GB201817385D0 (en) Therapy
GB201814038D0 (en) Ilven therapy
IL268046B1 (en) Peptides for therapy
GB201906026D0 (en) Target
GB201806463D0 (en) Cancer therapy
GB201809828D0 (en) Combined hormal therapy
GB201801152D0 (en) Cure for cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)